Primary adenocarcinoma of the seminal vesicles. A review of the literature

Abstract

Primary adenocarcinoma of the seminal vesicles (SV) are extremely rare and approximately only 60 cases have been reported in the literature. Due to the lack of specific symptoms the patients often present in an advanced stage of their disease. The only clinical examination that can indicate the presence of a neoplasm in the SVs is the digital rectal examination (DRE). Serum prostatic specific antigen (PSA) and prostate specific acid phosphatase (PAP) are usually normal in patients with primary adenocarcinoma of the SV and only CA-125 can be proved a useful blood biomarker contributing to the diagnosis and the follow up of the SV adenocarcinoma. Computed tomography (CT) and magnetic resonance imaging (MRI) and FDG-PET/CT have been used for the diagnosis and the staging of the SV adenocarcinoma. Various combinations of radical surgery, radiotherapy androgen deprivation therapy and chemotherapy have been proposed for the management of the disease but the prognosis is poor and the mean survival is two years after the diagnosis.

A case of primary adenocarcinoma of the seminal vesicle treated by total laparoscopic pelvic exenteration

“…DRE, CT, and MRI are useful for diagnosis of adenocarcinoma of the SV. DRE commonly reveals a painless, palpable mass (~70 % of patients) [1,4,5]. While the serum PSA level is normal, CA125 is a useful diagnostic and therapeutic marker for adenocarcinoma of the SV, initially showing an elevated level but falling if the patient responds to treatment [2].…”

“…4 Microphotographs of hematoxylin and eosin stain. a × 40. b × 400. clear cells had nuclei with increased chromatin and formed irregular tubular glands Tochigi Kosuke et al A case of … Akt Urol androgen deprivation therapy have been proposed [1]. Radical resection is considered essential.…”

“…Er zeigt 19 Monate nach der Operation keine Anzeichen eines Rezidivs. therapy, chemotherapy, and androgen deprivation therapy have been proposed [1,4,6].…”

Metastatic primary seminal vesicle adenocarcinoma: management of a rare tumour with multiagent chemotherapy and hormonal therapy

“…The tumour was a poorly differentiated adenocarcinoma and the immunostaining pattern was showing negative staining for PSA, PSAP, CK 20 and CEA along with a strong positivity for CK7 corresponding with the immunostaining pattern observed in previously reported cases 2–11. Other histological types that have been reported include sarcomas, squamous cell carcinomas, lymphomas, germ cell tumours, gastrointestinal stromal tumor and neuroendocrine tumours 11. Benign tumours are even rarer and include cystic dysplasia, fibroepithelial tumours, leiomyoma, cystadenoma and schwannoma 11…”

Primary seminal vesicle adenocarcinoma: A case report of rare entity and discussion of its differential diagnosis using immunohistochemical approach for the core biopsy specimen

“…On IHC, these atypical cells lining the papillary structures were positive for CK7, CA125 and PAX-8, and negative for PSA, AMACR, CK20, CDX-2, p63, GATA3, WT1, and calretinin. The Ki-67 index is about 30%-40% in these cells ( Figure 2 PSVA is an extremely rare tumour, with about 100 cases reported in the literature (Campobasso, Fornia, Ferretti, Maestroni, & Cortellini, 2012;Egevad, Ehrnström, Håkansson, & Grabe, 2007;Katafigiotis et al, 2016;Montironi et al, 2014;Ormsby, Haskell, Jones, & Goldblum, 2000;Oxley, Brett, Gillatt, & Burton, 1999;Posenato et al, 2017;Terrisse et al, 2017;Thiel & Effert, 2002;Yin & Jiang, 2018). The mean age of presentation is 62 years (range, 17-90 years).…”